Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00124696 · ClinicalTrials.gov registry record · Phase 1

Cocaethylene as a Treatment for Cocaine Dependence - 1

A Phase 1 study of Cocaine-Related Disorders, sponsored by National Institute on Drug Abuse (NIDA).

Completed
Registry status
Phase 1
Development phase
8
Enrollment target
1
Study location

NCT00124696 is a Phase 1 study of Cocaine-Related Disorders that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 8 participants, below the 64-participant average among 15 other Cocaine-Related Disorders trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00124696, a Phase 1 study of Cocaine-Related Disorders, has completed, sponsored by National Institute on Drug Abuse (NIDA).

COMPLETED
Registry status
Phase 1
Development phase
8 participants
Enrollment target
1
Study location

Study Summary

Cocaine has been cited as the primary drug threat in the United States. The purpose of this study is to determine if cocaethylene, used as a prototype drug, is a safe and effective treatment for cocaine dependence.

Conditions Studied

Interventions

  • DRUG Cocaethylene

Study Locations (1)

Virginia

  • Virginia Commonwealth University - Richmond

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2002-12
Est. Completion 2005-03
Phase Phase 1

What the Registry Record Tells You About NCT00124696

The ClinicalTrials.gov registry entry for NCT00124696 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 64-participant average among 15 other Cocaine-Related Disorders trials with a reported enrollment target (87% lower). The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cocaine-Related Disorders appearing as the primary indexed condition, and to 1 intervention - of which Cocaethylene is the first listed.

NCT00124696 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.

Frequently Asked Questions

What is clinical trial NCT00124696 about?

NCT00124696 is a clinical study titled "Cocaethylene as a Treatment for Cocaine Dependence - 1". Cocaine has been cited as the primary drug threat in the United States. The purpose of this study is to determine if cocaethylene, used as a prototype drug, is a safe and effective treatment for cocaine dependence.

What is the current status of trial NCT00124696?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2002-12. Estimated completion is 2005-03.

What conditions does trial NCT00124696 study?

This clinical trial studies the following conditions: Cocaine-Related Disorders.

What interventions are being tested in trial NCT00124696?

The interventions under investigation include: Cocaethylene (DRUG).

Who is sponsoring clinical trial NCT00124696?

This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00124696 being conducted?

This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cocaine-Related Disorders

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.